1. Home
  2. PFX vs SGMT Comparison

PFX vs SGMT Comparison

Compare PFX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PFX
  • SGMT
  • Stock Information
  • Founded
  • PFX 2010
  • SGMT 2006
  • Country
  • PFX United States
  • SGMT United States
  • Employees
  • PFX N/A
  • SGMT N/A
  • Industry
  • PFX Finance: Consumer Services
  • SGMT
  • Sector
  • PFX Finance
  • SGMT
  • Exchange
  • PFX Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • PFX 99.3M
  • SGMT 93.7M
  • IPO Year
  • PFX N/A
  • SGMT 2023
  • Fundamental
  • Price
  • PFX $46.00
  • SGMT $4.73
  • Analyst Decision
  • PFX
  • SGMT Strong Buy
  • Analyst Count
  • PFX 0
  • SGMT 5
  • Target Price
  • PFX N/A
  • SGMT $21.60
  • AVG Volume (30 Days)
  • PFX 1.1K
  • SGMT 792.4K
  • Earning Date
  • PFX 12-20-2024
  • SGMT 11-13-2024
  • Dividend Yield
  • PFX N/A
  • SGMT N/A
  • EPS Growth
  • PFX 36.92
  • SGMT N/A
  • EPS
  • PFX 9.66
  • SGMT N/A
  • Revenue
  • PFX $22,293,269.00
  • SGMT N/A
  • Revenue This Year
  • PFX $19.50
  • SGMT N/A
  • Revenue Next Year
  • PFX $9.74
  • SGMT N/A
  • P/E Ratio
  • PFX $4.76
  • SGMT N/A
  • Revenue Growth
  • PFX 14.03
  • SGMT N/A
  • 52 Week Low
  • PFX $36.50
  • SGMT $2.31
  • 52 Week High
  • PFX $50.00
  • SGMT $20.71
  • Technical
  • Relative Strength Index (RSI)
  • PFX 33.76
  • SGMT 41.81
  • Support Level
  • PFX $44.56
  • SGMT $5.61
  • Resistance Level
  • PFX $47.11
  • SGMT $6.40
  • Average True Range (ATR)
  • PFX 0.61
  • SGMT 0.53
  • MACD
  • PFX -0.20
  • SGMT -0.16
  • Stochastic Oscillator
  • PFX 26.47
  • SGMT 8.24

About PFX PhenixFIN Corporation

PhenixFIN Corp formerly Medley Capital Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Share on Social Networks: